Zinbryta (daclizumab)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- daclizumab
- Company
- Biogen Idec Ltd
- Status
- Withdrawn
- Therapeutic area
- Multiple Sclerosis
- CHMP opinion
- Thu 31 Mar 2016
- EU approval
- Fri 01 Jul 2016
- Designations
- Additional monitoring
- Application
- EMEA/H/C/003862
- ATC
- L04AC01
- Official record
- www.ema.europa.eu
Indication
Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zenapax Withdrawn · Roche Registration Ltd.
Follow Zinbryta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.